297 related articles for article (PubMed ID: 30955858)
1. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
2. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
3. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
[TBL] [Abstract][Full Text] [Related]
5. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
7. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
8. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
9. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
Olsen JB; Cao XJ; Han B; Chen LH; Horvath A; Richardson TI; Campbell RM; Garcia BA; Nguyen H
Mol Cell Proteomics; 2016 Mar; 15(3):892-905. PubMed ID: 26750096
[TBL] [Abstract][Full Text] [Related]
12. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Kawata A; Honjoh H; Kawata Y; Kashiyama T; Sato M; Taguchi A; Miyamoto Y; Tanikawa M; Tsuruga T; Nagasaka K; Wada-Hiraike O; Osuga Y; Fujii T
Oncol Lett; 2020 Nov; 20(5):153. PubMed ID: 32934721
[TBL] [Abstract][Full Text] [Related]
13. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
14. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
17. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
18. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
Bitler BG; Bailey CA; Yamamoto TM; McMellen A; Kim H; Watson ZL
Mol Carcinog; 2023 Nov; 62(11):1717-1730. PubMed ID: 37493106
[TBL] [Abstract][Full Text] [Related]
19. The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.
Piao L; Kang D; Suzuki T; Masuda A; Dohmae N; Nakamura Y; Hamamoto R
Neoplasia; 2014 Mar; 16(3):257-64, 264.e2. PubMed ID: 24726141
[TBL] [Abstract][Full Text] [Related]
20. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
